Clinical trials: Botulinum toxin type A
Spasticity
Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Lower Limb Spasticity
Phase 2/3, randomized, double-blind, placebo-controlled, single-treatment, multicenter trial assessing the efficacy and safety of MYOBLOC for the treatment of lower limb spasticity, in adults followed by an open-label extension…
- Trial name
- NCT04099667
- Testing
- Phase 2; Low Dose MYOBLOC (15,000 Units), Phase 2; High Dose MYOBLOC (20,000 Units), Phase 3; MYOBLOC
- Where
- 9 sites in United States, Hungary and 1 more
- Volunteers
- 40 people
- Sponsor
- Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC
Obstructed Defecation Syndrome (ODS)
Effects of Botox in Obstructed Defecation Syndrome
The purpose of this study is to determine if Botulinum Toxin-A (Botox) injection will improve symptoms of constipation in obstructed defecation syndrome (ODS).
- Trial name
- NCT02160288
- Testing
- Botulinum Toxin-A, Normal Saline
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Massachusetts General Hospital
Glabellar Frown Lines
Safety Study of DWP-450 (Botulinum Purified Neurotoxin, Type A) Injection to Treat Glabellar Lines
The purpose of this study is to demonstrate the safety of multiple doses of DWP-450 (Botulinum purified neurotoxin, Type A) Injection in treatment of moderate to severe glabellar lines in adult subjects.
- Trial name
- EV-004 (NCT02184988)
- Testing
- Botulinum purified neurotoxin, Type A
- Where
- United States
- Volunteers
- 352 people, healthy volunteers welcome
- Sponsor
- Evolus, Inc.
Glabellar Frown Lines
Safety Study of DWP-450 (Botulinum Toxin, Type a) to Treat Glabellar Lines - EV-006
The primary objective is to demonstrate the safety of multiple doses of DWP-450 purified Botulinum neurotoxin, Type A, in treatment of moderate to severe glabellar lines associated with corrugator and procerus muscle activity in…
- Trial name
- EV-006 (NCT02428608)
- Testing
- DWP-450 (Botulinum purified neurotoxin, Type A)
- Where
- United States
- Volunteers
- 570 people, healthy volunteers welcome
- Sponsor
- Evolus, Inc.
Vasculogenic Erectile Dysfunction
Intracavernosal Injection of Botulinum Toxin Type A in the Treatment of Vascular Erectile Dysfunction
Evidence has been arising that Botulinum toxin injections can relax smooth muscles fibers in the treatment of obesity and hyperactive bladder.
- Trial name
- NCT02584686
- Testing
- Botulinum Toxin Type A, Normal Saline
- Where
- Egypt
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Cairo University
Urinary Incontinence
A Multi-Center Trial of Botox for Severe Urge Urinary Incontinence
The purpose of the study is to determine how effective Botox is in reducing the amount of urine leaked and which dose of Botox is more effective and safe in those who have urinary urge incontinence.
- Trial name
- NCT00345332
- Testing
- Botox
- Where
- 3 sites in United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- University of Rochester
Overactive Bladder, Urinary Incontinence
Long Term Follow-up Study of Safety and Efficacy of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence
The purpose of this study is to assess the long term safety and effectiveness of botulinum toxin type A in treating patients with idiopathic overactive bladder with urinary incontinence.
- Trial name
- NCT00915525
- Testing
- botulinum toxin Type A
- Where
- 8 sites in United States, Belgium and 6 more
- Volunteers
- 829 people
- Sponsor
- Allergan
Post-Stroke Spasticity, Cerebrovascular Accident
Study of GSK1358820 In Patients With Post-Stroke Lower Limb Spasticity
This is a study to confirm the superior efficacy of GSK1358820 over placebo in patients with equinus deformity associated with post-stroke lower limb spasticity using the Modified Ashworth Scale (MAS) ankle score.
- Trial name
- NCT00460655
- Testing
- GSK1358820
- Where
- 20 sites in Japan
- Volunteers
- 120 people
- Sponsor
- GlaxoSmithKline
Chronic Troublesome Sialorrhea, Cerebral Palsy
Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual Disability
The objective of this study is to investigate the efficacy and safety of NT 201 compared with placebo for the treatment of chronic troublesome sialorrhea associated with neurological disorders (e.g.
- Conditions
- Chronic Troublesome Sialorrhea, Cerebral Palsy, Stroke, Traumatic Brain Injury
- Trial name
- SIPEXI (NCT02270736)
- Testing
- NT 201
- Where
- 31 sites in Georgia, Hungary and 4 more
- Volunteers
- 256 people
- Sponsor
- Merz Pharmaceuticals GmbH
Neurogenic Bladder Dysfunction Nos, Spinal Cord Injury
Botox-A Injection to Improve Bladder Function in Early Spinal Cord Injury (#H-20344)
The purpose of this study is to see what the effect of Botox has on bladder function for those who have recently suffered spinal cord injury.
- Trial name
- NCT00711087
- Testing
- BOTOX-A, Saline injection
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Baylor College of Medicine
Painful Bladder Syndrome, Interstitial Cystitis
Botox as a Treatment for Interstitial Cystitis in Women
Patients with interstitial cystitis have been well documented to have pelvic floor muscle tenderness as well as pain on bladder distension.
- Trial name
- NCT00194610
- Testing
- Botox, normal saline
- Volunteers
- 20 people
- Sponsor
- University of Washington
Migraine Disorders
Efficacy and Safety Study of BOTOX® Compared to Topiramate for the Prevention of Chronic Migraine in Adults
This study will evaluate the efficacy, safety and tolerability of prophylactic (preventative) treatment with BOTOX® (onabotulinumtoxinA) compared to topiramate in adults with chronic migraine.
- Trial name
- NCT02191579
- Testing
- onabotulinumtoxinA, Topiramate
- Where
- 32 sites in United States
- Volunteers
- 282 people
- Sponsor
- Allergan
Cerebral Palsy, Muscle Spasticity
Dysport® Pediatric Lower Limb Spasticity Study
The purpose of this research study is to determine whether Dysport® is effective in the treatment of increased stiffness of the calf muscles and to evaluate the safety of this treatment in children with Cerebral Palsy.
- Conditions
- Cerebral Palsy, Muscle Spasticity, Children
- Trial name
- NCT01249417
- Testing
- Botulinum toxin type A
- Where
- 29 sites in United States, Chile and 4 more
- Volunteers
- 241 people
- Sponsor
- Ipsen
Lateral Canthal Lines, LCL, Crow's Feet
ET-01 in Subjects With Lateral Canthal Lines, LCL-209
This study tests an investigational drug formulation called ET-01, botulinum toxin, Type A, topical, in lateral canthal lines (LCL).
- Trial name
- NCT03912805
- Testing
- botulinum toxin, Type A, Vehicle
- Where
- 3 sites in United States
- Volunteers
- 38 people
- Sponsor
- Eirion Therapeutics Inc.
Raynaud's Disease
A Two-Part Study of BOTOX® Therapy for Ischemic Digits
Treating patients with Raynaud's phenomenon who have chronic pain and ulcerations is extremely challenging. Published reports and our previous work support our hypothesis that symptomatic patients experience relief of pain and…
- Trial name
- NCT01309802
- Testing
- onabotulinum toxin type-A
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Southern Illinois University
Wrinkles in Frontal Area
Field of Effects of Two Commercial Preparations of Botulinum Toxin Type A
The objective of this study is to compare the field of effects of the botulinum toxins (Dysport® and Botox®) using two equivalence-ratios and to gather supportive information, such as more detailed data on the effectiveness in…
- Trial name
- NCT00989768
- Testing
- Botulinum Toxin Type A (Dysport®), Botulinum Toxin Type A/Botox®, Botulinum Toxin Type A/Dysport®
- Where
- Brazil
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Hexsel Dermatology Clinic
Cervical Dystonia, Blepharospasm
A Retrospective Chart Review of BOTOX® and Xeomin® for the Treatment of Cervical Dystonia and Blepharospasm
This study is a retrospective chart review to evaluate the doses of botulinum Type A toxins BOTOX® (onabotulinumtoxinA) and Xeomin® (incobotulinumtoxinA) used for the treatment of Cervical Dystonia and Blepharospasm in clinical…
- Trial name
- NCT01814774
- Testing
- No Intervention
- Where
- 2 sites in Norway, United Kingdom
- Volunteers
- 48 people
- Sponsor
- Allergan
Facial Rhytides, Skin Folds
Study to Evaluate Subject Satisfaction With Facial Appearance and Impact of Combined Facial Treatment
The primary objective of this study is to quantify the psychological, social, and emotional impact of comprehensive aesthetic treatment with a portfolio of the Sponsor's products by measuring the change in subject's satisfaction…
- Conditions
- Facial Rhytides, Skin Folds, Loss of Volume and Skin Quality
- Trial name
- NCT04609020
- Testing
- JUVÉDERM, BOTOX, HArmonyCA Lidocaine
- Where
- 6 sites in Brazil
- Volunteers
- 64 people
- Sponsor
- Allergan
Essential Tremor of the Upper Limb
A Study to Investigate the Efficacy and Safety of NT 201 (Botulinum Toxin) Compared With Placebo for the Treatment of Adult Participants With Essential Tremor in the Arm
The purpose of this study is to determine whether a single treatment with NT 201 (botulinum toxin) is superior to placebo (no medicine) for one-sided treatment of essential tremor in the motor-dominant arm (Unilateral Period).
- Trial name
- NCT04766723
- Testing
- NT 201
- Where
- 14 sites in United States, Canada and 1 more
- Volunteers
- 78 people
- Sponsor
- Merz Pharmaceuticals GmbH
Upper Limb Spasticity
IncobotulinumtoxinA (Xeomin) for Upper Limb Spasticity
This study will investigate the efficacy and safety of incobotulinumtoxinA (Xeomin) in the treatment of arm tightness (upper limb spasticity) using two different dilutions of incobotulinumtoxinA (Xeomin).
- Trial name
- NT-Spin (NCT00465738)
- Testing
- incobotulinumtoxinA (Xeomin, also known as "NT 201" or "Botulinum toxin type A (150 kD), free from complexing proteins")
- Where
- 27 sites in Austria, France and 6 more
- Volunteers
- 216 people
- Sponsor
- Merz Pharmaceuticals GmbH